New product introductions offset slightly weaker Q4 results due to COVID-19 headwinds and international pressure.
While the Trauma segment was not impacted as heavily due to COVID-19 headwinds, companies that play within the space were impacted by deferrals of elective surgeries such as limb restoration. Long bone trauma volumes remained healthy as players cited new product introductions as growth drivers for the segment.
Among the many topics covered in detail in our comprehensive Q421/FY21 Trauma Market Recap* are: